Hearing the name Spravato for the first time? Start here
Answers to the questions people ask in their first ten minutes with the word: what it is, where it happens, what it costs, and safety.
Most people meet the word Spravato cold. Before our survey reached them, 73 percent of the 443 adults we polled had never come across it. If you just ran into the name yourself, this page takes the questions people ask in the first ten minutes, in roughly that order, and assumes you are starting from zero. It is general information, not medical advice.
What is Spravato?
Spravato is what the maker calls its esketamine, a medicine you breathe in as a nasal spray. The FDA has cleared it for adults with treatment-resistant depression, taken alongside an antidepressant pill, and also for adults with major depression who are in an acute suicidal crisis. Its distribution is restricted, so only certified clinics can give it.
What does "treatment-resistant" mean? It sounds like a verdict.
It describes a medication history, not a person. Loosely, it means major depression still hanging on after two or more antidepressants, each given a fair dose and a fair stretch of time. It does not mean untreatable, and it does not mean you failed.
The situation is ordinary. Our respondents told us that depression, anxiety, or PTSD that medicine could not settle had reached 72 percent of them, personally or through someone close. That breaks down as 37 percent themselves, 22 percent a loved one, and 13 percent both; 28 percent had no such experience.
Is this the same as ketamine?
Related, but not the same in practice. Ketamine is a molecule with two mirror-image halves, and esketamine is one of them, made into a spray and approved for the uses above. Ketamine dripped into a vein at an infusion clinic is an anesthetic used off label. Ketamine shipped to your door after a video visit is a third model, with the least oversight of all.
When someone says "ketamine treatment," ask which one they mean. The answer changes the approval status, the supervision, the evidence, and the bill.
Where would I actually go?
Through a prescriber first. That is also what most of our respondents said. Their primary care doctor was the first choice of 56 percent, a psychiatrist or therapist of 23 percent, and a web search of 12 percent. Asking a friend drew 1 percent, and 5 percent were simply unsure how they would begin. That majority route is practical too, since your current prescriber already holds the history eligibility depends on.
Can I do it at home?
Not with the approved spray. You take it under watch at a certified site, wait out a monitoring period, and someone else drives.
What people want does not always line up with that. In our results, 44 percent preferred an in-person clinic. Video care at home got 22 percent and a clinic start with a later move home 23 percent, and 11 percent were indifferent. If convenience matters most to you, say so early, because it changes which options are really on the table.
What happens during a session?
Broadly, you give yourself the dose under supervision, then stay for a set period while staff check on you, blood pressure included. Effects can include dissociation, a sense of being detached from yourself or the room, plus dizziness, nausea, and sleepiness. That is why the monitoring window exists and why you need a ride.
Will insurance pay for it?
That depends on your plan, and it is the question most likely to settle things. Coverage outranked everything when our respondents chose a provider: it sat in the top two for 85 percent. Distance from home ranked second at 43 percent. Speedy results drew 24 percent, FDA approval 27, with privacy on 11 and a veteran or first responder focus on 10.
We also asked how much insurance would weigh on the choice to start treatment at all. It would be the deciding factor for 22 percent and a big factor for 43 percent, which combined is 65 percent. For 21 percent it would count for something, and 14 percent said it would not enter into it.
Before booking, call your plan. Ask if the treatment is covered, if prior authorization applies, which records of earlier medication trials they need, and whether the site has to be in network. To see how one certified clinic explains the process and the costs, read Brain Recovery Centers' guide to Spravato treatment with those answers in hand.
What if it is not covered? Should I just pay?
Our respondents were split. We asked them to choose between insured care that comes with extra steps and a self-pay route with a quicker start. Half, 51 percent, would put up with the steps. Just 23 percent would pay to move faster, and the last 26 percent were unsure.
If you pay, get the whole course priced in writing.
Does what kind of insurance I have matter?
A great deal, because each plan type has its own rules. Our sample was mixed, with commercial coverage checked by 39 percent, Medicaid by 37, Medicare by 23, no insurance by 9, and TRICARE by 5. A clinic that takes insurance may not take yours, so ask by plan name.
Is there a version without drugs at all?
Yes. Depression care also includes psychotherapy and transcranial magnetic stimulation, or TMS, which uses a device instead of a medicine. Few of our respondents knew about it: only 25 percent. Yet a medication-free route appealed to 64 percent, most of whom had never heard of TMS. Ask your clinician for the whole menu, not one item.
Is it safe?
No medicine is safe for everyone, and this one has known risks, which is exactly why it is given under supervision. Whether benefits outweigh risks for you depends on your history, your blood pressure, your other prescriptions, and any history with substances. That is a clinician's call, not an article's.
What should I do next?
List how long you have struggled, what you have taken and for how long, and what has changed. Bring that list to a prescriber.
Thoughts of ending your life deserve help tonight, not next week. Any phone in the U.S. reaches the national Lifeline at 988, by voice or text; it is free, private, and staffed at every hour.
Methodology
The publisher commissioned this first-party study and paid for it. Pollfish recruited 443 adults, ages 18 to 64, from its consumer panel across ten Midwest states, and the survey closed June 23, 2026. Each person consented at the start. On multi-select questions we give the percentage choosing each answer, so those columns sum past 100. Everything reported here postdates the panel's final validation.